Extended-release wax-matrix nicotinic acid supports lipid and lipoprotein metabolism, study shows
Highlights
- 6-month blinded, crossover study (n=31 adults)
- Extended-release, wax-matrix nicotinic acid supports lipid and lipoprotein (apo-A1 and apo-B) metabolism
- Treatment reported to be well tolerated
Summary
This clinical study was designed to assess the effects and tolerance of extended-release, wax-matrix nicotinic acid (WMNA) in the treatment of dyslipidemia in 31 patients with Types IIa and IIb hyperlipoproteinemias. The study was a 6-month blinded, crossover study.
Results indicate WMNA treatment reduced total cholesterol by 9-13%, reduced low-density lipoprotein (LDL) cholesterol by 12-22%, and increased high-density lipoprotein (HDL) cholesterol by 12-15%. Moreover, WMNA treatment resulted in improvements in blood lipid transport proteins, including a 12-16% increase in apoprotein AI and 29% decrease in apoprotein B. Treatment was reported to be well tolerated by patients.
These findings indicate WMNA has clinical value in treating familial hypercholesterolemia.
